[SCHEDULE 13G/A] MEI Pharma, Inc. SEC Filing

Rhea-AI Filing Summary

Alexander Schornstein reported beneficial ownership of 4,365,472 shares of MEI Pharma, Inc. common stock, representing 13.29% of the outstanding class. This holding includes 4,140,472 shares directly held by Mr. Schornstein and 225,000 shares held by Camino Capital GmbH, of which he is the sole beneficial owner with sole voting and dispositive power. The filing states these shares were purchased from August 11, 2025 through September 9, 2025 using the Reporting Person's personal funds and that ownership exceeded the 10% threshold on September 9, 2025.

The filer certifies the securities were not acquired to influence control of the issuer and is filing under the short-form Schedule 13G provision. The percentage is calculated using 32,837,743 shares outstanding as disclosed in the companys Form S-3 Amendment No. 1 dated August 26, 2025. The filing identifies the issuers principal executive office in San Diego, CA and provides the Reporting Persons address in Aachen, Germany.

Positive

• Material disclosure of a >10% stake provides transparency to the market
• Sole voting and dispositive power over the reported shares is clearly stated
• Percentage basis disclosed using 32,837,743 shares outstanding from the issuers Form S-3 amendment

Negative

• None.

Insights

Securities Analyst

TL;DR: A non-U.S. individual crossed the 10% ownership threshold, filing a Schedule 13G and asserting passive intent.

The Schedule 13G/A shows Mr. Alexander Schornstein amassed a 13.29% stake in MEI Pharma using personal funds and consolidated voting and dispositive power over 4,365,472 shares. Filing under Rule 13d-1(c) indicates the Reporting Person represents a passive investor rather than an activist seeking control. The disclosed share count basis is 32,837,743 shares outstanding from the issuer's Form S-3 amendment, providing a clear denominator for the percentage calculation. For investors, a >10% holder is material for ownership concentration and potential future signal, but the filers certification of non-control intent confines this to a monitoring item unless actions change.

Corporate Governance Expert

TL;DR: Ownership concentration is notable; governance implications depend on future actions, not on this passive filing alone.

The report documents sole voting and dispositive power over a meaningful minority stake (13.29%). That level of ownership typically warrants attention from boards and shareholders because it can enable influence if coordinated or increased. However, the explicit statement that securities were not acquired to influence control and the use of Schedule 13G rather than Schedule 13D indicate the Reporting Person currently claims passive intent. From a governance perspective, this filing is material for disclosure and monitoring but does not, by itself, constitute an immediate governance event.

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

(Amendment No. 1)

MEI Pharma, Inc.

(Name of Issuer)

Common Stock, par value $0.001

(Title of Class of Securities)

55279B301

(CUSIP Number)

09/09/2025

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

SCHEDULE 13G

CUSIP No. 55279B301

1

Names of Reporting Persons

Alexander Schornstein

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

GERMANY

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 4,365,472.00
6	Shared Voting Power 0.00
7	Sole Dispositive Power 4,365,472.00
8	Shared Dispositive Power 0.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

4,365,472.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

13.29 %

12

Type of Reporting Person (See Instructions)

IN

SCHEDULE 13G

Item 1.
(a)	Name of issuer: MEI Pharma, Inc.
(b)	Address of issuer's principal executive offices: 9920 Pacific Heights Blvd., Suite 150 San Diego, CA, 92121
Item 2.
(a)	Name of person filing: Alexander Schornstein
(b)	Address or principal business office or, if none, residence: Kaiser-Friedrich-Allee 2, 52074 Aachen Germany 004915142314669
(c)	Citizenship: Germany
(d)	Title of class of securities: Common Stock, par value $0.001
(e)	CUSIP No.: 55279B301
Item 3.	If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)	Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)	Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)	Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)	Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)	An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)	An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)	A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)	A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)	A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)	A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:
(k)	Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.	Ownership
(a)	Amount beneficially owned: 4,365,472 Includes 4,140,472 shares of Common Stock held by Alexander Schornstein and 225,000 shares of Common Stock held by Camino Capital GmbH, in which Alexander Schornstein is the sole beneficial owner and has sole voting power. As disclosed in the Company's report on Form 8-K filed with the United States Securities and Exchange Commission on September 10, 2025, the Company, pursuant to an amendment to its amended and restated certificate of incorporation filed with the Secretary of State of the State of Delaware, has changed his name to Lite Strategy, Inc. effective September 10, 2025 and will being trading under its new name and symbol "LITS" on September 11, 2025. On the period from August 11, 2025 to September 9, 2025, the Reporting Person made several purchases of the Issuer's shares, causing ownership to exceed ten percent on September 9, 2025. Consideration for the shares was obtained from the personal funds of the Reporting Person. The Reporting Person did not acquire the securities with any purpose, or with the effect, of changing or influencing the control of the issuer, or in connection with or as a participant in any transaction having that purpose or effect, and is thus eligible to file a short-form statement on Schedule 13G pursuant to ss. 240.13d-1(c) of the Securities Exchange Act of 1934.
(b)	Percent of class: 13.29% Based upon 32,837,743 shares of common stock currently issued and outstanding, as stated in the Company's registration statement on Form S-3 Amendment No. 1 filed with the United State Securities and Exchange Commission on August 26, 2025, prior to the completion of the offering contemplated by the registration statement.
(c)	Number of shares as to which the person has:
	(i) Sole power to vote or to direct the vote: 4,365,472
	(ii) Shared power to vote or to direct the vote: 0
	(iii) Sole power to dispose or to direct the disposition of: 4,365,472
	(iv) Shared power to dispose or to direct the disposition of: 0
Item 5.	Ownership of 5 Percent or Less of a Class.
Item 6.	Ownership of more than 5 Percent on Behalf of Another Person.
	Not Applicable
Item 7.	Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
	Not Applicable
Item 8.	Identification and Classification of Members of the Group.
	Not Applicable
Item 9.	Notice of Dissolution of Group.
	Not Applicable

Item 10.

Certifications:

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Alexander Schornstein

Signature:	/s/ Alexander Schornstein
Name/Title:	Alexander Schornstein
Date:	09/10/2025

FAQ

How many shares of MEIP does Alexander Schornstein report owning?

The filing reports 4,365,472 shares of MEI Pharma common stock.

What percentage of MEIP does this ownership represent?

The ownership represents 13.29% of the outstanding common stock based on 32,837,743 shares.

Did the filer state the purpose of the acquisition?

Yes, the filer certifies the securities were not acquired to influence control and is filing under Schedule 13G.

When did the Reporting Person exceed the 10% ownership threshold?

Ownership exceeded 10% on September 9, 2025 according to the filing.

Does the filing indicate where the shares were sourced from?

The filing states consideration for the shares was obtained from the personal funds of the Reporting Person.